UFP Technologies, Inc.

What they do

UFP designs and manufactures custom, often customer-specified medical products, including protective drapes for robotic surgery, patient handling and comfort products, advanced wound care, infection prevention items, disposables for surgical and endoscopic procedures, packaging for medical devices and orthopedic implants, cardiac implant components, catheter dispenser coils, and biopharma drug manufacturing components. It operates 19 ISO 13485-certified manufacturing locations, 13 of which are FDA-registered, and sells primarily to medical device manufacturers. The company also runs a smaller non-medical business.

Revenue drivers

• Medical market products — The core business — single-use and single-patient devices and packaging across minimally invasive surgery, infection control, orthopedics, wound care, and biopharma. Medical sales grew 23.2% in 2025 and represented the large majority of net sales; two customers, Intuitive Surgical SARL and Stryker Corporation, accounted for 24.3% and 21.5% of 2025 net sales respectively.
• Acquired businesses (2024 and 2025 acquisitions) — Acquired companies contributed approximately $168.3 million in 2025 sales versus $73.1 million in 2024, and were the main driver of the 19.5% total sales increase; organic growth was only 1.5% in 2025.
• Existing customer program growth — In Q2 2026, the top five customers grew 14.7% and the balance of the MedTech business grew 19.7% year over year, while the non-medical business was flat. Organic sales growth was 12.4% in Q2 2026.

Recent performance

Q2 2026 net sales were a record $174.0 million, up 15.1% from $151.2 million in Q2 2025, and net income was $20.9 million, up 21.4%. GAAP diluted EPS was $2.68 and adjusted EPS was $2.92. Gross margin rose to 29.3% from 28.8%, and operating income grew 15.5% to $28.1 million, though SG&A rose 21.8% to $22.8 million (13.1% of sales). For the first half of 2026, sales were $328.2 million (up 9.6%) and net income was $38.3 million (up 11.6%), with GAAP EPS of $4.92 and adjusted EPS of $5.39.

Strategy

Management states its strategy is further organic growth plus growth through strategic acquisitions. In Q2 2026 it said it continues to invest in its Dominican Republic operations to support customer-driven growth, expand capacity, and improve cost structure over time, though it noted the full benefits are taking longer than anticipated and are creating near-term mix and margin pressure in U.S. operations. The company also said it added executives in business development, operations, and legal to support growth. It continues to pursue disciplined acquisitions and new program launches with existing customers.

Risks

• Customer concentration — Intuitive Surgical SARL and Stryker Corporation together were 45.8% of 2025 net sales, so loss or reduction of either would materially affect results.
• AJR labor issue — A post-acquisition E-Verify review of the AJR workforce caused significant turnover, and the company estimates the issue added over $6.3 million in incremental labor cost to 2025 cost of sales.
• Tariffs and trade policy — Increased U.S. tariffs on imports affect the countries where UFP manufactures and where its customers operate, and the tariff environment remains dynamic; unreimbursed tariffs were immaterial to 2025 results but future actions are unpredictable.
• Cyber incident — A cyber incident was detected on or about February 14, 2026; the company says it has not had a material impact on financial systems, operations, or financial condition so far, but investigation is ongoing and future impacts cannot be assured against.

Outlook

Management says it sees meaningful opportunities to grow with existing customers, support new program launches, pursue disciplined acquisitions, and invest in people and capabilities. It describes the fundamentals of its markets as attractive and emphasizes disciplined execution and long-term value creation. It also cautioned that benefits from the Dominican Republic investments are taking longer than anticipated to fully realize and are pressuring near-term U.S. mix and margins.